Moleculin Biotech Equity 2024

Moleculin Biotech Aktienanalyse

What does Moleculin Biotech do?

Moleculin Biotech Inc is a biopharmaceutical company based in Houston, Texas, that focuses on the development of innovative cancer therapies. The company was founded in 2015 and has since made significant progress in the research and development of drugs for the treatment of cancer. The company follows an innovative business model consisting of two main divisions: research and development, as well as distribution. Moleculin Biotech focuses on identifying compounds that target specific types and stages of cancer in order to enable personalized cancer treatment. The company currently has several projects in the pipeline, each with the potential to change the way cancer is treated. In the research department, Moleculin Biotech focuses on identifying compounds that target cancer types that have been difficult to treat. The company is dedicated to developing effective drugs that can inhibit cell division in certain types of cancer and stop their growth. The critical goal is to develop medications that selectively attack cancer cells without affecting healthy cells. The distribution department of Moleculin Biotech is responsible for marketing and distributing the developed drugs. The company has a well-established network of distribution partners and agencies that help with the introduction of new products. Moleculin Biotech aims to distribute its products worldwide and continuously expand its patient base. One of Moleculin Biotech's key products is the compound WP1122. This molecule is a prodrug capable of selectively accumulating and acting in cancer cells. As a result, it can be used in combination with other cancer therapies to increase treatment efficacy. The company has already demonstrated the potential of WP1122 in clinical trials and is currently working on its market launch. Another significant product of Moleculin Biotech is Annamycin. This is a chemotherapeutic specifically developed for the treatment of leukemia. The medication has already been tested in clinical trials and proven to be effective. Annamycin has the potential to dramatically change and improve the treatment of leukemia. In addition to these two products, Moleculin Biotech also has MSP-2017 in its portfolio. This anti-tumor drug specifically targets pancreatic cancer and has the potential to increase the survival rate of patients in advanced stages of the disease. MSP-2017 is currently still in the development phase and is expected to enter the market in the coming years. Overall, Moleculin Biotech is a promising company focusing on the development of innovative cancer therapies. The company has the potential to fundamentally change cancer treatment and save the lives of millions of people worldwide. The company is committed to intensifying its research and development activities and continuously expanding its product pipeline. Moleculin Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Moleculin Biotech's Equity

Moleculin Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Moleculin Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Moleculin Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Moleculin Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Moleculin Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Moleculin Biotech stock

What is the equity of Moleculin Biotech this year?

Moleculin Biotech has equity of 26.07 M USD this year.

What was the equity of Moleculin Biotech compared to the previous year?

The equity of Moleculin Biotech has increased/decreased by -50.04% decreased compared to the previous year.

What impact does a high equity have on investors of Moleculin Biotech?

A high equity is advantageous for investors of Moleculin Biotech as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Moleculin Biotech?

A low equity can be a risk for investors of Moleculin Biotech, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Moleculin Biotech affect the company?

An increase in equity of Moleculin Biotech can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Moleculin Biotech affect the company?

A reduction in equity of Moleculin Biotech can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Moleculin Biotech?

Some factors that can affect the equity of Moleculin Biotech include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Moleculin Biotech so important for investors?

The equity of Moleculin Biotech is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Moleculin Biotech take to change the equity?

To change equity, Moleculin Biotech can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Moleculin Biotech pay?

Over the past 12 months, Moleculin Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Moleculin Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Moleculin Biotech?

The current dividend yield of Moleculin Biotech is .

When does Moleculin Biotech pay dividends?

Moleculin Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Moleculin Biotech?

Moleculin Biotech paid dividends every year for the past 0 years.

What is the dividend of Moleculin Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Moleculin Biotech located?

Moleculin Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Moleculin Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Moleculin Biotech from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Moleculin Biotech pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Moleculin Biotech in the year 2023?

In the year 2023, Moleculin Biotech distributed 0 USD as dividends.

In which currency does Moleculin Biotech pay out the dividend?

The dividends of Moleculin Biotech are distributed in USD.